Skip to main content

Cepheid Gets Canadian Clearance of MRSA/SA Test

NEW YORK (GenomeWeb News) – Cepheid today said that Canadian regulatory authorities have cleared for marketing the firm’s molecular diagnostic assay for methicillin-resistant Staphylococcus aureus and Staphylococcus aureus in skin and soft tissue infections.
 
The Xpert MRSA/SA SSTI test runs on Cepheid’s GeneXpert System and can provide test results in less than an hour. The firm noted that its test is the first molecular SSTI diagnostic for MRSA and SA to be cleared in Canada.
 
Cepheid received US Food and Drug Administration clearance for the test in September.
 
This is the fifth of Cepheid’s tests to gain Canadian clearance. It also has a MRSA/SA Blood Culture test and Xpert HemosIL test under regulatory review in Canada.
 

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.